In recent years, there has been an exponential increase in the global burden of cancer
which has been associated with several factors including environmental influence, aging, diet,
infectious agents, hormonal imbalance and chronic inflammation, among others. Cancerous cells
utilize more glucose for their proliferation and survival than normal cells. Thus, the regulation of
glucose consumption of cancerous cells through the inhibition of glucose transporter-4-protein
(GLUT4) encoded by solute carrier family-2-member-4-gene (Slc2a4) by selected phytochemicals
from Solanum xanthocarpum may serve as a new therapeutic candidate for the treatment of cancer.
The seven identified potential inhibitors of GLUT4 from Solanum xanthocarpum were retrieved from
PubChem database. Examination of their drug-likeness, toxicity prediction and molecular docking
studies of these compounds with GLUT4 were carried out using online tools such as Molinspiration,
PreADMET V.2.0 and Patchdock server. The findings revealed that five out of the seven compounds
fulfil oral drugability of Lipinski’s rule of five (RO5) while two slightly meet the criteria of RO5.
Conversely, five of the compounds are predicted to be mutagen while the remaining two are predicted
to be safe for the body. Additionally, stigmasterol glucoside has higher binding-affinity (7590) with
GLUT4 when compared to doxorubicin (6600) the control. These findings suggest that stigmasterol
glucoside from Solanum xanthocarpum could be a promising therapeutic agent with better therapeutic
efficacy than doxorubicin in the treatment of cancer via the inhibition of GLUT4.